Prof Jorge Reis-Filho talks to ecancer about molecularly characterising triple negative breast cancer at IMPAKT 2012 in Brussels, May 2012.

At the molecular level, triple negative breast cancer is not a single disease. There are a larger number of heterogeneous tumours, which means that this disease cannot be analysed in the same way as other types of breast cancer.

The differences between diseases are the biological starting point for testing different therapeutic agents against triple negative breast cancer. The different subtypes of tumours can each respond differently to strategies, but will give prognostic signatures that will point to a quick and clear prognosis. However, there are complications with what type of prognostic signatures can be used in triple negative cases.

Filming Supported by Amgen